Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    (Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
    (Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
    (Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
    (Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
    Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
    ... , , , , , , , ... , , 1691112, 100 g, ... Package Inserts/Product , Instructions , , German , ... version - 54 K , , US Material Safety , ...
    ... , , , Catalog Number, ... 1691104, Set, , , , ... , English , version - 24 K , ... US Material Safety , Data Sheets , , ...
    ... Here are some troubleshooting hints that we have gathered , regarding misincorporation or low fidelity of PCR reactions: , , ... , , , ... , <a , ... , , <a , ...
    Cached Biology Technology:Trouble-shooting: Misincorporation or low fidelity 2Trouble-shooting: Misincorporation or low fidelity 3
    (Date:4/15/2014)... University of Missouri researchers have previously shown that ... to exercise exists. In a new study, Frank Booth, ... has found a potential link between the genetic pre-disposition ... at which mental maturation occurs. , For his study, ... extreme activity or extreme laziness. Booth then put the ...
    (Date:4/15/2014)... The global experts who study the deadliest infectious ... Thomas G. Ksiazek, professors at the University of Texas ... 6th annual International Symposium on Filoviruses. The filoviruses include ... to 90 percent of people infected. The current outbreak ... more than 100 deaths so far. , "This ...
    (Date:4/15/2014)... pastoral landscapes are some of the loveliest in the ... of the country,s pasture soils have become enriched in ... is then eaten by the cattle and sheep that ... Zealand; cadmium-enriched soils being reported worldwide. , The concern ... in meat and dairy products, human health and New ...
    Breaking Biology News(10 mins):Genetic pre-disposition toward exercise and mental development may be linked 2International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3
    ... Alzheimer,s is set to take a step forward following ... automated 3D microscopy. An initiative between the ... Institute for Cellular and Molecular Biology, the technology will ... as complex as nerve cells in the brain. ...
    ... is available in French . Vancouver, B.C. -- ... place at the wrong time. As a result of changing conditions, marine ... as three kilometres per year over the past 50 years, and forecasts ... years. Decisions on where to put MPAs weren,t always made with ...
    ... years, biologists have been amazed by the power of gecko ... roughly equivalent to carrying nine pounds up a wall without ... at the University of Massachusetts Amherst have discovered exactly how ... device that can hold 700 pounds on a smooth wall. ...
    Cached Biology News:Marine protected areas: changing climate could require change of plans 2Inspired by gecko feet, UMass Amherst scientists invent super-adhesive material 2
    ... Combining linear motor and ballscrew ... pre-engineered Cartesian solutions that include ... management, and motors., , ... Pass through high-flex cabling for ...
    UGT1A6 (D-20)...
    ... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
    ... designed for moving loads quickly and accurately. ... output while limiting overall size. The P5S-P ... ball bearings guided on two rails., ... provide energy absorption and controlled deceleration , ...
    Biology Products: